CN101744844B - Fulvic acid or sodium fulvate substance with hypoglycemic function - Google Patents
Fulvic acid or sodium fulvate substance with hypoglycemic function Download PDFInfo
- Publication number
- CN101744844B CN101744844B CN2009102183557A CN200910218355A CN101744844B CN 101744844 B CN101744844 B CN 101744844B CN 2009102183557 A CN2009102183557 A CN 2009102183557A CN 200910218355 A CN200910218355 A CN 200910218355A CN 101744844 B CN101744844 B CN 101744844B
- Authority
- CN
- China
- Prior art keywords
- fulvic acid
- sodium fulvate
- sulfuric acid
- acid ester
- fulvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 title claims abstract description 87
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 85
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 85
- 239000011734 sodium Substances 0.000 title claims abstract description 85
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 229940095100 fulvic acid Drugs 0.000 title claims abstract description 84
- 239000002509 fulvic acid Substances 0.000 title claims abstract description 84
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 12
- 239000000126 substance Substances 0.000 title claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 52
- 239000005017 polysaccharide Substances 0.000 claims abstract description 52
- -1 polysaccharide sulfate Chemical class 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 230000036541 health Effects 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003077 lignite Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940126701 oral medication Drugs 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000011953 bioanalysis Methods 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 10
- 150000001720 carbohydrates Chemical class 0.000 abstract description 5
- 235000014633 carbohydrates Nutrition 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 229940100688 oral solution Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 239000000243 solution Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 239000004021 humic acid Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000013527 cardiovascular neoplasm Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000020339 pu-erh tea Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010193 shuanglong Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Abstract
The invention relates to a health care product and a drug, in particular to a fulvic acid or sodium fulvate substance health care product and a drug with hypoglycemic function; the fulvic acid or sodium fulvate substance with hypoglycemic function is provided, in particular to the health care product, and the health care product is oral solution, the ingredients of the oral solution are as follows by mass percentage: 1-10 percent of the fulvic acid or the sodium fulvate, 0.5-10 percent of polysaccharide sulfate and the remaining is water; the fulvic acid or sodium fulvate substance health care product can remarkably reduce the content of the blood sugar, total cholesterol and triglycercide of diabetics, increase the oral carbohydrate tolerance, and has a function of regulating blood sugar level; the fulvic acid or sodium fulvate substance health care product is a purely natural product, is safe and reliable and has no toxic and side effect, thereby being the health care product which can meet the needs of people.
Description
Technical field
The present invention relates to a kind of health product and medicine, particularly relate to a kind of fulvic acid or sodium fulvate health product and medicine with hypoglycemic activity.
Background technology
Diabetes are a kind of more common chronic metabolic diseases of whole body by gene and the common decision of environment, and main feature is a chronic hyperglycemia, and follows sugar, protein and the fat metabolic disturbance that is caused by insulin secretion obstacle and insulin action defective.The classical symptom of diabetes is " three-many-one-littles ", i.e. drinking a lot of water, and diet is many; Frequent micturition and losing weight is controlled and badly will be caused many general complication, and for example: cardiovascular, kidney and neural chronic diseases become; Have a strong impact on human health, and threaten patient's life.
Along with the progress of society, great change has taken place in people's dietary structure, and diabetes prevalence also constantly rises.In many countries such as America and Europes, the mortality rate of diabetes is very high, after cardiovascular disease and tumor, classifies the 3rd as.At present, global diabetics reaches 1.5 hundred million people, expects onset diabetes rate in 2025 and will be outburst trend, will increase to 300,000,000, and wherein the diabetics number of China, India will reach 40% of the whole world.Because people constantly increase the needs of health, diabetes are paid close attention to by people day by day.
People are not limited only to blood sugar lowering to the requirement of antidiabetic drug now; Also requiring has blood fat reducing in blood sugar lowering, improve the functions such as carbohydrate tolerance of diabetics, has or not toxicity, action temperature with, slowly and lasting, the advantage of stable in properties.Because in the natural product, often multiple cofactor combined effect, multiple sugar-lowering components is also deposited.So it is significant in natural drug, to seek the medicine of blood sugar lowering safely and effectively and control diabetic complication.
Fulvic acid is that a kind of degree of oxidation is high, and it is many to contain active function groups, the utilization that is prone to be absorbed by the body, a kind of humic acids that medical effect is best.Before several thousand, Li Shizhen (1518-1593 A.D.) is the existing medicinal record of similar humic acids in Compendium of Material Medica, mainly reaches diseases such as all sores, incised wound are hemorrhage bitterly in order to treatment nosebleed, women's QI and blood.But do not see the report that fulvic acid and the effect of sodium fulvate aspect blood sugar lowering are arranged in the prior art.
Summary of the invention
The object of the present invention is to provide a kind of fulvic acid or sodium fulvate health product and medicine with hypoglycemic activity.
The present invention is based on theabrownin of Pu'er tea and fulvic acid aspect chemical property (structure and functional group) and have certain similarity; Infer that fulvic acid and sodium fulvate should have similarity in physiologically active and treatment function aspects and tea pigment; Should have function of blood sugar reduction; Therefore, develop following technical proposals of the present invention and realize the object of the invention:
Have the fulvic acid or the sodium fulvate material of hypoglycemic activity, this material is composed of the following components by mass percentage:
Fulvic acid or sodium fulvate 1% ~ 10%
Polysaccharide sulfuric acid ester 0.5% ~ 10%
Its surplus of water
The preferential content 2% of recommending fulvic acid or sodium fulvate, polysaccharide sulfuric acid ester 0.5, water surplus.
Fulvic acid of the present invention extracts with chemical method or bioanalysis; Sodium fulvate adopts the neutralisation preparation, and sodium fulvate serves as that the preparation of acid-base neutralization method is adopted on the basis with the fulvic acid that extracts.The polysaccharide sulfuric acid ester extracts with water extraction.
Fulvic acid or sodium fulvate health product that the present invention has hypoglycemic activity are the oral liquid formulations that contain fulvic acid or sodium fulvate.
The present invention also provides application and the application in the preparation health-caring product capable of reducing blood sugar in the preparation hypoglycemic drug of fulvic acid or sodium fulvate.
The method for preparing of fulvic acid of the present invention or sodium fulvate medicine comprises the steps:
1) preparation of fulvic acid and sodium fulvate:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate;
2) preparation of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester;
3) get 1) gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → by weight percentage fulvic acid or sodium fulvate 1% ~ 10%, polysaccharide sulfuric acid ester 0.5% ~ 10% adds polysaccharide sulfuric acid ester → mix → add pharmaceutical carrier by the conventional way of oral drugs to process fulvic acid or sodium fulvate drug oral medicament.
The method for preparing of fulvic acid or sodium fulvate health product is provided simultaneously, comprises the steps:
1) preparation of fulvic acid and sodium fulvate:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate;
2) preparation of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester;
3) get 1) gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → by mass percentage fulvic acid or sodium fulvate 1% ~ 10%, polysaccharide sulfuric acid ester 0.5% ~ 10% adds polysaccharide sulfuric acid ester → mix → fully dissolving → sterilization → bottling → fulvic acid or sodium fulvate health product.
The present invention compares with existing hypoglycemic drug, has the following advantages:
1, the present invention can obviously reduce the content of blood glucose, T-CHOL, triglyceride in the diabetes human body, increases diabetes patient's carbohydrate tolerance, has obvious hypoglycemic effect.
2, the invention belongs to all-natural product, safe and reliable, have no side effect, sour-sweet mouthfeel is arranged, be fit to drink.
3, method for preparing of the present invention is simple, and cost consumption is low, has economic advantage.
Description of drawings:
Fig. 1 is the result of variations of mice body weight in fulvic acid and the sodium fulvate acute toxicity testing.
Specific embodiments:
Below in conjunction with accompanying drawing, further specify essentiality content of the present invention with the embodiment of the invention, but do not limit the present invention with this.
Embodiment 1-8:
Embodiment 1-8 all carries out with following step:
1. prepare fulvic acid and sodium fulvate, its preparation technology's flow process is following:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate.
2. it is following to extract the technological process of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester.
3. the preparation technology of preparation health product of the present invention is following:
Get 1 gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → fulvic acid or sodium fulvate 1% ~ 10% by mass percentage, polysaccharide sulfuric acid ester 0.5% ~ 10% adds polysaccharide sulfuric acid ester → mix → fully dissolving → sterilization → bottling → fulvic acid or sodium fulvate health product.
The one-tenth component selections of the health product that embodiment 1-8 is prepared is seen table 1.
Table 1 health product composition of the present invention (in quality %)
In above-mentioned implementing process flow process, case study on implementation ratio, can process bottled oral liquid health product with sober-up and anti-drunk function.
Embodiment 9:
1) contain the medication preparation of fulvic acid and sodium fulvate:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate;
2) preparation of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester;
3) get 1) gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → by mass percentage fulvic acid or sodium fulvate 4%; Polysaccharide sulfuric acid ester 0.5% adding polysaccharide sulfuric acid ester → mix → add pharmaceutical carrier by the conventional way of oral drugs is processed fulvic acid or sodium fulvate drug oral medicament.
Can process bottled oral administration solution health product or the medicine with hypoglycemic activity of the present invention by the foregoing description.Do pharmacologic action and the pharmacological action that following animal experiment example is explained product of the present invention with above-mentioned health product of the present invention or medicine:
Test Example 1:
The animal experiment study of hypoglycemic activity of the present invention
1. main experimental apparatus and reagent material
1.1 main experimental apparatus
ELIASA: Molecular Devices company; Micro centrifuge: Anting Scientific Instrument Factory, Shanghai; Balance: the two outstanding test instrunment in Changshu factory; Liquid-transfering gun (2 μ L): Dragon Medical(Shanghai) Co., Ltd..
1.2 main agents and material
Alloxan: Sigma company; Glucose enzyme process blood sugar detection box, triglyceride test kit, cholesterol reagent box: ShangHai RongSheng Biology Pharmacy Co., Ltd; Glucose (analytical pure): Tianjin Fengchuan Chemical Reagent Science & Technology Co., Ltd.; Metformin hydrochloride: Shenzhen Haiwang Pharmaceutical Co., Ltd.
Humic acids, sodium fulvate and polysaccharide sulfuric acid ester: the preparation of this lab assistant.
" Handilong " sodium fulvate: provide by the logical Handilong humic acids company limited of Xinjiang remittance.
" two dragon " sodium fulvate: provide by Xinjiang Shuanglong Humate and Humic Acid Co., Ltd..
Kunming mice: buy the male mouse of kunming number of clean level from unming Medical College, adaptability is fed 2-3d, chooses body weight 18 ~ 22g mice and experimentizes.
2. experimental technique
2.1 acute toxicity testing
Get 20 kunming mices, body weight is 18-22g, is divided into 2 groups, 10 every group, and male and female half and half.Water 12h is can't help in fasting, irritates stomach respectively for two groups and gives fulvic acid and sodium fulvate with 5g/kg dosage, observes 14d, and the dead mouse number respectively organized in record, and measured the mice body weight in per two days.
2.2 influence to normal mouse blood sugar
Get 64 Male Kunming strain mice; Be divided into 8 groups at random; Every group 8; It is the blank group; The metformin hydrochloride positive controls, low (1% fulvic acid+0.5% polysaccharide sulfuric acid ester), in (2% fulvic acid+0.5% polysaccharide sulfuric acid ester), high (4% fulvic acid+0.5% polysaccharide sulfuric acid ester) concentration fulvic acid group (laboratory self-control), low (1% sodium fulvate+0.5% polysaccharide sulfuric acid ester), in (2% sodium fulvate+0.5% polysaccharide sulfuric acid ester), height (4% sodium fulvate+0.5% polysaccharide sulfuric acid ester) concentration sodium fulvate group (laboratory self-control).Each organizes mice by 0.2ml/10g body weight gastric infusion, and the blank group is irritated stomach equal-volume distilled water, every day gastric infusion, 7d continuously.After water 12h is can't help in fasting after the last administration, get blood, press blood sugar detection test kit time-and-motion study blood glucose value in mouse tail vein.
2.3 alloxan modeling experiment
Get male mice, water 12h is can't help in fasting.Alloxan is made into fresh 2% solution with physiological saline solution, and intraperitoneal injection, dosage are 250mg/kg.For preventing dead mouse 4.5～5h behind intraperitoneal injection, irritate the stomach mice with mass fraction 50% glucose, every dosage is the 0.2mL/10g body weight.After one week, getting tail vein and detect fasting glucose, is diabetic mice with the mice of blood glucose more than 11.1mmol/L, becomes the mould integral animal to show the symptom of " three-many-one-little ", promptly takes food, drinking-water and hydrouria, and diabetic symptom such as lose weight.To become the mould mice to include experiment in.
2.4 influence (carbohydrate tolerance test) to blood glucose in diabetic mice
The mice that modeling is successful is divided into 11 groups at random by blood glucose value and body weight; Every group 8: the blank group; Model control group; The metformin hydrochloride positive controls; " Handilong " (2% sodium fulvate+0.5% polysaccharide sulfuric acid ester) group; " two dragon " (2% sodium fulvate+0.5% polysaccharide sulfuric acid ester) group, low (1% fulvic acid+0.5% polysaccharide sulfuric acid ester), in (2% fulvic acid+0.5% polysaccharide sulfuric acid ester), high (4% fulvic acid+0.5% polysaccharide sulfuric acid ester) concentration fulvic acid group (laboratory self-control), low (1% sodium fulvate+0.5% polysaccharide sulfuric acid ester), in (2% sodium fulvate+0.5% polysaccharide sulfuric acid ester), height (4% sodium fulvate+0.5% polysaccharide sulfuric acid ester) concentration sodium fulvate group (laboratory self-control).Each organizes mice by 0.2ml/10g body weight gastric infusion, and blank group and model control group all give isopyknic distilled water, irritate stomach every day once, continuous irrigation stomach 12d.Water 12h is can't help in the mice fasting 11d evening, tail vein measuring blood sugar of blood extracting, triglyceride and cholesterol level behind the morning next day gastric infusion 1.5h.Experimental session respectively at 6d, 12d respectively fasting tail vein get blood examination and survey blood glucose.12d evening respectively to model group, matched group, basic, normal, high concentration fulvic acid group and sodium fulvate group (laboratory self-control) the mice fasting can't help water 12h, get blood from the tail vein and survey fasting glucose morning next day.Gastric infusion behind the survey blood glucose is irritated stomach 2.5g/kg glucose behind the 1h, respectively at 0.5h, and 1h, 2h measures blood glucose value by tail vein blood.
Assay method: the content of measuring blood glucose in the blood plasma, cholesterol and triglyceride according to the description of glucose enzyme process blood sugar detection box, triglyceride test kit and cholesterol reagent box respectively.
Blood extracting method: the tail vein is got blood, and 4 ℃ leave standstill centrifugal behind the 1h (3000r/min, 1min) preparation serum.
2.5 statistical procedures data
Adopt one factor analysis of variance or student-t inspection statistics in the spss statistical software to analyze result of experiment, represent, P＜0.05 expression significant difference, P＜0.01 expression difference highly significant with X ± S.
3. result and analysis
3.1 acute toxicity testing result
The filling stomach is given fulvic acid and the sodium fulvate with 5g/kg dosage, observes 14d, and dead phenomenon does not appear in two groups of mices of result.Two groups of mice body weight change results see accompanying drawing 1.Can get fulvic acid and sodium fulvate can be considered nontoxic by above result.
3.2 normal mouse blood sugar value influenced result's (seeing table 2).
Table 2 fulvic acid and sodium fulvate to the influence of normal mouse blood sugar (x ± s, n=10)
Annotate: compare with blank control group: * * P＜0.01; Compare #P＜0.05, ##P＜0.01 with matched group.
3.3 blood glucose in diabetic mice influenced result's (seeing table 3).
Table 3 humic acids and sodium fulvate to the blood glucose in diabetic mice value influence the result (x ± s, n=10)
Annotate: compare * P＜0.05 with model group.
3.4 diabetic mice triglyceride, T-CHOL influenced result's (seeing table 4).
Table 4 fulvic acid and sodium fulvate to diabetic mice triglyceride, T-CHOL influence the result (x ± s, n=10)
Annotate: compare with model group: * P＜0.05, * * P＜0.01.
3.5 the oral glucose tolerance experimental result (seeing table 5) of diabetic mice.
Table 5 fulvic acid and sodium fulvate to the diabetic mice oral glucose tolerance influence the result (x ± s, n=10)
Annotate: compare * P＜0.05, * * P＜0.01 with model group; Compare with matched group: #P＜0.05.
4. conclusion:
Prove through above experiment; Fulvic acid and sodium fulvate health product can obviously reduce the content of blood glucose, T-CHOL, triglyceride in the mice body; Increase the carbohydrate tolerance of mice, therefore draw the effect that the health product that contain fulvic acid and sodium fulvate and medicine have blood sugar lowering.
Claims (10)
1. have the fulvic acid or the sodium fulvate material of hypoglycemic activity, this material is composed of the following components by mass percentage:
Fulvic acid or sodium fulvate 1%～10%
Polysaccharide sulfuric acid ester 0.5%～10%
Its surplus of water.
2. according to the described material of claim 1, wherein the content of fulvic acid or sodium fulvate is 2%, polysaccharide sulfuric acid ester 0.5%, water surplus.
3. according to the described material of claim 1, it is characterized in that fulvic acid extracts with chemical method or bioanalysis; Described sodium fulvate adopts the neutralisation preparation.
4. according to the described material of claim 1, it is characterized in that sodium fulvate is serves as that the preparation of acid-base neutralization method is adopted on the basis with the fulvic acid that extracts.
5. according to the described material of claim 1, described polysaccharide sulfuric acid ester extracts with water extraction.
6. the oral liquid formulations that contains claim 1 fulvic acid or sodium fulvate.
7. claim 1 fulvic acid or the sodium fulvate application in the preparation hypoglycemic drug.
8. claim 1 fulvic acid or the sodium fulvate application in the preparation health-caring product capable of reducing blood sugar.
9. the method for preparing of described fulvic acid of claim 1 or sodium fulvate medicine comprises the steps:
1) preparation of fulvic acid and sodium fulvate:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate;
2) preparation of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester;
3) get 1) gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → by weight percentage fulvic acid or sodium fulvate 1%～10%, polysaccharide sulfuric acid ester 0.5%～10% adds polysaccharide sulfuric acid ester → mix → add pharmaceutical carrier by the conventional way of oral drugs to process fulvic acid or sodium fulvate drug oral medicament.
10. the method for preparing of described fulvic acid of claim 1 or sodium fulvate health product comprises the steps:
1) preparation of fulvic acid and sodium fulvate:
Brown coal → crushing screening → get fine breeze → add hydrogen peroxide degrade → get upper strata liquid → centrifugal sucking filtration → get solution → drying → bullion fulvic acid → purification by macroporous resin → must make with extra care fulvic acid → add NaOH → sodium fulvate;
2) preparation of polysaccharide sulfuric acid ester:
Thallus Laminariae (Thallus Eckloniae) → add water heating extraction → get solution → concentrate → twice purification of bullion polysaccharide sulfuric acid ester → ethanol → must make with extra care the polysaccharide sulfuric acid ester;
3) get 1) gained fulvic acid or sodium fulvate → add water to stir → fully dissolving → by mass percentage fulvic acid or sodium fulvate 1%～10%, polysaccharide sulfuric acid ester 0.5%～10% adds polysaccharide sulfuric acid ester → mix → fully dissolving → sterilization → bottling → fulvic acid or sodium fulvate health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102183557A CN101744844B (en) | 2009-12-14 | 2009-12-14 | Fulvic acid or sodium fulvate substance with hypoglycemic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102183557A CN101744844B (en) | 2009-12-14 | 2009-12-14 | Fulvic acid or sodium fulvate substance with hypoglycemic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101744844A CN101744844A (en) | 2010-06-23 |
| CN101744844B true CN101744844B (en) | 2012-05-30 |
Family
ID=42472859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102183557A Expired - Fee Related CN101744844B (en) | 2009-12-14 | 2009-12-14 | Fulvic acid or sodium fulvate substance with hypoglycemic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101744844B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404894B (en) * | 2013-08-20 | 2014-07-30 | 昆明理工大学 | Processing technology for flavor duck gizzards |
| CN103462085B (en) * | 2013-09-24 | 2014-12-31 | 昆明理工大学 | Spicy eel and preparation method thereof |
| CN103519214B (en) * | 2013-10-12 | 2014-10-01 | 昆明理工大学 | Low-salt flavor poultry meat and preparation method thereof |
| CN105832860A (en) * | 2016-05-04 | 2016-08-10 | 昆明理工大学 | Fulvic acid oral liquid capable of resisting altitude stress and preparation method thereof |
| JP7038424B2 (en) * | 2018-01-29 | 2022-03-18 | 株式会社スタイルアンドバリュージャパン | Food composition for improving or preventing lifestyle-related diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101033231A (en) * | 2007-04-29 | 2007-09-12 | 晋城市炬坤生物科技有限公司 | Method of preparing high-purity medical xanthonumic acid |
-
2009
- 2009-12-14 CN CN2009102183557A patent/CN101744844B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101033231A (en) * | 2007-04-29 | 2007-09-12 | 晋城市炬坤生物科技有限公司 | Method of preparing high-purity medical xanthonumic acid |
Non-Patent Citations (1)
| Title |
|---|
| 袁明霞等.黄腐酸钠对糖尿病大鼠视网膜病变的作用.《微循环学杂志》.2001,第11卷(第1期),11-13. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101744844A (en) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101744844B (en) | Fulvic acid or sodium fulvate substance with hypoglycemic function | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| CN103520199A (en) | Application of lycium barbarum polysaccharide in diabetes treating medicine | |
| CN104922176A (en) | Application of flos chrysanthemi indici extract | |
| CN112961262A (en) | Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN101862346A (en) | Hypoglycemic application of gingseng acidic polysaccharide | |
| CN101721425A (en) | Fulvic acid health-care product with sober-up and anti-drunk function | |
| CN107129541A (en) | A kind of preparation method and applications of burdock polysaccharide pyrogen | |
| CN101554406B (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN102028703B (en) | New application of inulin | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN106265717A (en) | Dicliptera chinensis polysaccharide application in preparation preventing and treating diabetes medicament or health product | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN112979839A (en) | Preparation method of passion flower leaf acidic polysaccharide | |
| CN101829271A (en) | Chinese medicinal compound with function of treating diabetes and preparation method and application thereof | |
| CN101204504A (en) | Medicament composite for diabetes mellitus and preparation method threreof | |
| CN107281408A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: 653100 Yuxi science and Technology Development Zone, Yunnan hi tech Park incubator building C105, No. 106 Patentee after: YUNNAN HIGH GRADE BIOTECHNOLOGY CO., LTD. Address before: 650093 Kunming Province, Wuhua District, road, No. 253 (Kunming University of Science and Technology) Patentee before: Kunming Science and Engineering Univ |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20191214 |